Imatinib mesylate and nilotinib affect MHC-class i presentation by modulating the proteasomal processing of antigenic peptides

Cancer Immunology, Immunotherapy

Volumn 62, Issue 4, 2013, Pages 715-726

  Held, Stefanie Andrea Erika ^a   Duchardt, Katharina Maria ^c   Tenzer, Stefan ^b   Rückrich, Thomas ^c   Von Schwarzenberg, Karin ^a   Bringmann, Anita ^a   Kurts, Christian ^f   Schild, Hansjörg ^b   Driessen, Christoph ^d   Brossart, Peter ^a,e   Heine, Annkristin ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e Medizinische Klinik III   (Germany)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

Antigen processing; Chronic myeloid leukemia; Imatinib; Nilotinib; Proteasome

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMINO ACID; BCR ABL PROTEIN; BORTEZOMIB; EPITOPE; HLA A3 ANTIGEN; HLA B8 ANTIGEN; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NILOTINIB; PROTEASOME; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; BETA CHAIN; BIOTINYLATION; CHRONIC MYELOID LEUKEMIA; COVALENT BOND; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LEUKEMIA CELL LINE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BENZAMIDES; FUSION PROTEINS, BCR-ABL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; K562 CELLS; LEUKEMIA; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; PROTEIN PHOSPHATASE 2; PYRIMIDINES;

EID: 84877820487     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1373-7     Document Type: Article

References (45)

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082
2. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990) Acute leukaemia in bcr/abl transgenic mice. Nature 344:251-253. doi: 10.1038/344251a0
3. Hochhaus A, O'Brien SG, Guilhot F et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061. doi: 10.1038/leu.2009.38
4. Kantarjian HM, O'Brien S, Cortes J et al (2003) Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98:2636-2642. doi: 10.1002/cncr.11831
5. Roy L, Guilhot J, Krahnke T et al (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108:1478-1484. doi: 10.1182/blood-2006-02-001495
6. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942
7. O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004. doi: 10.1056/NEJMoa022457
8. Snead JL, O'Hare T, Eide CA, Deininger MW (2008) New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided? Clin Lymphoma Myeloma 8(Suppl 3):S107-S117. doi: 10.3816/CLM.2008.s.006
9. Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-2541. doi: 10.1056/NEJMoa055229
10. Heine A, Held SA, Bringmann A, Holderried TA, Brossart P (2011) Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25:899-905. doi: 10.1038/leu.2011.24
11. Appel S, Boehmler AM, Grunebach F et al (2004) Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103:538-544. doi: 10.1182/blood-2003-03-0975
12. Balabanov S, Appel S, Kanz L, Brossart P, Brummendorf TH (2005) Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells. Ann N Y Acad Sci 1044:168-177. doi: 10.1196/annals.1349.022
13. Appel S, Rupf A, Weck MM, Schoor O, Brummendorf TH, Weinschenk T, Grunebach F, Brossart P (2005) Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res 11:1928-1940. doi: 10.1158/1078-0432.CCR-04-1713
14. Brauer KM, Werth D, von Schwarzenberg K, Bringmann A, Kanz L, Grunebach F, Brossart P (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res 67:5489-5497. doi: 10.1158/0008-5472.CAN-07-0302
15. Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR, Krusch M (2010) The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 127:2119-2128. doi: 10.1002/ijc.25233
16. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A (2005) Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105:2473-2479. doi: 10.1182/blood-2004-07-2527
17. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094-1099. doi: 10.1182/blood-2003-12-4266
18. Reichardt VL, Brossart P (2005) Current status of vaccination therapy for leukemias. Curr Hematol Rep 4:73-76
19. Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H (2003) Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 27:795-802
20. Weisberg E, Griffin JD (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95:3498-3505
21. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F, Brossart P (2005) PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 106:3888-3894. doi: 10.1182/blood-2004-12-4709
22. Appel S, Bringmann A, Grunebach F, Weck MM, Bauer J, Brossart P (2006) Epithelial-specific transcription factor ESE-3 is involved in the development of monocyte-derived DCs. Blood 107:3265-3270. doi: 10.1182/blood-2005-06-2480
23. le Coutre P, Kreuzer KA, Pursche S et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313-323. doi: 10.1007/s00280-003-0741-6
24. Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542-2551. doi: 10.1056/NEJMoa055104
25. Faivre S, Delbaldo C, Vera K et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35. doi: 10.1200/JCO.2005.02.2194
26. Strumberg D, Richly H, Hilger RA et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972. doi: 10.1200/JCO.2005.06.124
27. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ (2005) Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2:357-362. doi: 10.1038/nmeth759
28. Bogyo M, McMaster JS, Gaczynska M, Tortorella D, Goldberg AL, Ploegh H (1997) Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci USA 94:6629-6634
29. Kessler BM, Tortorella D, Altun M, Kisselev AF, Fiebiger E, Hekking BG, Ploegh HL, Overkleeft HS (2001) Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol 8:913-929
30. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grunebach F, Brossart P (2006) Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108:551-558. doi: 10.1182/blood-2005-08-3494
31. Nencioni A, Garuti A, Schwarzenberg K et al (2006) Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 36:681-689. doi: 10.1002/eji.200535298
32. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279
33. Tenzer S, Stoltze L, Schonfisch B, Dengjel J, Muller M, Stevanovic S, Rammensee HG, Schild H (2004) Quantitative analysis of prion-protein degradation by constitutive and immuno-20S proteasomes indicates differences correlated with disease susceptibility. J Immunol 172:1083-1091
34. Silva JC, Denny R, Dorschel CA et al (2005) Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 77:2187-2200. doi: 10.1021/ac048455k
35. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ (2006) Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics MCP 5:144-156. doi: 10.1074/mcp.M500230-MCP200
36. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680-2684
37. Clark RE, Dodi IA, Hill SC et al (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98:2887-2893
38. Posthuma EF, van Bergen CA, Kester MG et al (2004) Proteosomal degradation of BCR/ABL protein can generate an HLA-A,0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated. Haematologica 89:1062-1071
39. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111:5610-5620. doi: 10.1182/blood-2007-02-075945
40. Burchert A, Wolfl S, Schmidt M et al (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259-264. doi: 10.1182/blood-2002-02-0659
41. Borg C, Terme M, Taieb J et al (2004) Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Investig 114:379-388. doi: 10.1172/JCI21102
42. Crawford LJ, Windrum P, Magill L, Melo JV, McCallum L, McMullin MF, Ovaa H, Walker B, Irvine AE (2009) Proteasome proteolytic profile is linked to Bcr-Abl expression. Exp Hematol 37:357-366. doi: 10.1016/j.exphem.2008.11.004
43. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87:3587-3592
44. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, Lemonnier FA, Leblond V, Langlade-Demoyen P (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Investig 101:2290-2296. doi: 10.1172/JCI488
45. Lu H, Zong C, Wang Y et al (2008) Revealing the dynamics of the 20 S proteasome phosphoproteome: a combined CID and electron transfer dissociation approach. Mol Cell Proteomics MCP 7:2073-2089. doi: 10.1074/mcp.M800064-MCP200